Patents Examined by Jim Ketter
-
Patent number: 9086413Abstract: Malignant melanoma is the most aggressive type of skin cancer and currently accounts for more than 160.000 new cancer cases worldwide every year. Incidence of malignant melanoma is rapidly increasing—with a doubling rate of 10-20 years and a death rate of 11%. The inventors of the present application found genes that predict overall survival of patients with malignant melanoma and that contain prognostic information not comprised in the conventional histopathological and clinical criteria. Accordingly, the present invention relates to the field of oncology, more particularly to methods of predicting clinical outcome in malignant melanoma as defined in the claims.Type: GrantFiled: June 29, 2009Date of Patent: July 21, 2015Inventors: Georg Brunner, Jens Atzpodien
-
Patent number: 9085764Abstract: The present invention is directed generally to eukaryotic host cells comprising artificial endosymbionts and methods of introducing artificial endosymbionts into eukaryotic host cells. The invention provides artificial endosymbionts that introduce a phenotype to host cells that is maintained in daughter cells. The invention additionally provides eukaryotic host cells containing magnetotactic bacteria.Type: GrantFiled: December 24, 2014Date of Patent: July 21, 2015Assignee: Bell Biosystems, Inc.Inventors: Caleb Bell, III, Alexey Bazarov
-
Patent number: 9074241Abstract: There is disclosed a method comprising the steps of: carrying out a plurality of expression assays, each expression assay comprising the steps of: carrying out an intervention on a biological system, measuring an expression profile of non-coding RNAs in the biological system resulting from the intervention, and storing an expression data set derived from the measured expression profile, the said expression assays concerning either or both a plurality of different interventions and a plurality of different biological systems; and analysing the resulting expression data sets to determine correlations between the effect on the expression profile of non-coding RNAs of the respective intervention in groups of two or more expression assays concerning either or both different interventions or different biological systems.Type: GrantFiled: January 19, 2010Date of Patent: July 7, 2015Assignee: Sistemic Scotland LimitedInventors: Jacinto Peter Estibeiro, John Francis Gordon, Christopher Robert Hillier, Vincent O'Brien
-
Patent number: 9074206Abstract: The present invention relates compositions and methods for microRNA (miRNA) expression profiling of colorectal cancer. In particular, the invention relates to a diagnostic kit of molecular markers for identifying one or more mammalian target cells exhibiting or having a predisposition to develop colorectal cancer, the kit comprising a plurality of nucleic acid molecules, each nucleic acid molecule encoding a miRNA sequence, wherein one or more of the plurality of nucleic acid molecules are differentially expressed in the target cells and in one or more control cells, and wherein the one or more differentially expressed nucleic acid molecules together represent a nucleic acid expression signature that is indicative for the presence of or the predisposition to develop colorectal cancer.Type: GrantFiled: November 13, 2009Date of Patent: July 7, 2015Assignee: Fudan UniversityInventors: Ying Wu, Hongguang Zhu, Jian Li, Liang Xu, Wilhelmus F. J. Verhaegh, Yiping Ren, Angel Janevski, Vinay Varadan, Zhaoyong Li, Nevenka Dimitrova
-
Patent number: 9061059Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: GrantFiled: February 3, 2014Date of Patent: June 23, 2015Assignee: Moderna Therapeutics, Inc.Inventors: Tirtha Chakraborty, Antonin de Fougerolles, Ron Weiss
-
Patent number: 9051614Abstract: The present invention provides a new method for detecting or monitoring a liver disease in a subject that has no indication of any liver pathologies, by measuring the amount of concentration of albumin mRNA in an acellular blood sample from the subject, and then comparing the amount or concentration of albumin mRNA with a standard control.Type: GrantFiled: September 10, 2010Date of Patent: June 9, 2015Assignee: The Chinese University of Hong KongInventors: Yuk Ming Dennis Lo, Rossa Wai Kwun Chiu, Rebecca Wing Yan Chan
-
Patent number: 9051576Abstract: A recombinant yeast of the genus Komagataella which has been transformed with a galactose promoter is provided. The yeast is preferably Komagataella phaffii, and the promoter is preferably a S. cerevisiae GAL1 or GAL10 promoter. Vectors and methods for producing recombinant polypeptides are also provided.Type: GrantFiled: July 26, 2012Date of Patent: June 9, 2015Assignee: Fujifilm Diosynth Biotechnologies UK LimitedInventor: Bhupendra Vallabh Kara
-
Patent number: 9045721Abstract: A multilayered cell culture apparatus for the culturing of cells is disclosed. The cell culture apparatus is defined as an integral structure having a plurality of cell culture chambers in combination with tracheal space(s). The body of the apparatus has imparted therein gas permeable membranes in combination with tracheal spaces that will allow the free flow of gases between the cell culture chambers and the external environment. The flask body also includes an aperture that will allow access to the cell growth chambers by means of a needle or cannula. The size of the apparatus, and location of an optional neck and cap section, allows for its manipulation by standard automated assay equipment, further making the apparatus ideal for high throughput applications.Type: GrantFiled: December 18, 2013Date of Patent: June 2, 2015Assignee: Corning IncorporatedInventors: Gregory Roger Martin, Allison Jean Tanner
-
Patent number: 9044507Abstract: The present invention relates to the use of immunogenic peptides comprising a T-cell epitope derived from a viral vector antigen and a redox motif such as C-(X)2-[CST] or [CST]-(X)2-C in the prevention and/or suppression of immune responses to viral vectors and in the manufacture of medicaments therefore.Type: GrantFiled: February 16, 2009Date of Patent: June 2, 2015Assignees: LIFE SCIENCES RESEARCH PARTNERS VZW, KATHOLIEKE UNIVERSITEIT LEUVENInventor: Jean-Marie Saint-Remy
-
Patent number: 9040290Abstract: A multilayered cell culture apparatus for the culturing of cells is disclosed. The cell culture apparatus is defined as an integral structure having a plurality of cell culture chambers in combination with tracheal space(s). The body of the apparatus has imparted therein gas permeable membranes in combination with tracheal spaces that will allow the free flow of gases between the cell culture chambers and the external environment. The flask body also includes an aperture that will allow access to the cell growth chambers by means of a needle or cannula. The size of the apparatus, and location of an optional neck and cap section, allows for its manipulation by standard automated assay equipment, further making the apparatus ideal for high throughput applications.Type: GrantFiled: November 8, 2013Date of Patent: May 26, 2015Assignee: Corning IncorporatedInventors: Gregory Roger Martin, Allison Jean Tanner
-
Patent number: 9029419Abstract: The subject matter of the present invention is Zn N-acetyltaurinate of formula: [CH3—CO—NH—CH2—CH2—SO3]2?Zn2+ for preventing and/or treating diseases with lipofuscin accumulation due in particular to aging or to oxidative stress, and for preparing a medicament that is of use in treating these diseases. Use: treatment of diseases related to aging or to oxidative stress, in particular age-related macular degeneration and diabetic retinopathy.Type: GrantFiled: February 25, 2009Date of Patent: May 12, 2015Assignee: TRI-INOVInventor: Jean Durlach
-
Patent number: 9029519Abstract: The present invention provides a modified promoter, an expression vector and a transformant each containing the promoter, and a method for producing a gene product of interest using the transformant. The invention provides a modified promoter, including a nucleotide sequence of a promoter derived from bacterium belonging to the genus Bacillus in which at least one nucleotide sequence selected from the following has been modified: a nucleotide sequence represented by SEQ ID NO: 1; a nucleotide sequence equivalent to the nucleotide sequence represented by SEQ ID NO: 1, except that one or a plurality of bases therein are substituted, deleted, added or inserted; and a nucleotide sequence having a sequence identity of 70% or more with respect to the nucleotide sequence represented by SEQ ID NO: 1.Type: GrantFiled: October 18, 2010Date of Patent: May 12, 2015Assignee: Kao CorporationInventors: Akihito Kawahara, Hiroshi Kodama, Katsutoshi Ara
-
Patent number: 9023612Abstract: The present invention is directed generally to eukaryotic cells comprising single-celled organisms that are introduced into the eukaryotic cell through human intervention and which transfer to daughter cells of the eukaryotic cell, and methods of introducing such single-celled organisms into eukaryotic cells. The invention provides single-celled organisms that introduce a phenotype to eukaryotic cells that is maintained in daughter cells. The invention additionally provides eukaryotic cells containing magnetic bacteria. The invention further provides eukaryotic cells engineered with single-celled organisms to allow for multimodal observation of the eukaryotic cells. Each imaging method (or modality) allows the visualization of different aspects of anatomy and physiology, and combining these allows the imager to learn more about the subject being imaged.Type: GrantFiled: July 15, 2014Date of Patent: May 5, 2015Assignee: Bell Biosystems, Inc.Inventors: Caleb B. Bell, III, Alexey Bazarov
-
Patent number: 9012224Abstract: The present invention is based, in part, on the discovery that parvovirus (including AAV) capsids can be engineered to incorporate small, selective regions from other parvoviruses that confer desirable properties. The inventors have discovered that in some cases as little as a single amino acid insertion or substitution from a first parvovirus (e.g., an AAV) into the capsid structure of another parvovirus (e.g., an AAV) to create a chimeric parvovirus is sufficient to confer one or more of the desirable properties of the first parvovirus to the resulting chimeric parvovirus and/or to confer a property that is not exhibited by the first parvovirus or is present to a lesser extent.Type: GrantFiled: January 3, 2011Date of Patent: April 21, 2015Assignees: The University of North Carolina at Chapel Hill, The University of Florida Research FoundationInventors: Dawn E. Bowles, Chengwen Li, Joseph E. Rabinowitz, Josh Grieger, Mavis Agbandje-McKenna, Richard Jude Samulski
-
Patent number: 9012179Abstract: The present invention relates to a method for mass-producing an antifreeze protein derived from a polar yeast, and more particularly, to a method for mass-producing an antifreeze protein derived from Leucosporidium sp., which is the polar yeast, for synthesizing a recombinant polynucleotide by optimizing and altering a gene, which codes the antifreeze protein derived from the polar yeast, for a yeast expression system, and for expressing same using the yeast expression system.Type: GrantFiled: May 17, 2011Date of Patent: April 21, 2015Assignee: Korea Ocean Research and Development InstituteInventors: Hakjun Kim, Sungho Kang, Junhyuck Lee, Sunggu Lee, Sejong Han, Jongchan Park, Kyoungsun Park
-
Patent number: 9012154Abstract: The present invention relates to methods for detecting Ficolin-3 dependent activation of the lectin pathway of complement, methods for identifying abnormalities in Ficolin-3, and methods for screening for deficiencies/and or identifying abnormalities in any downstream components of the Ficolin-3 dependent activation of the lectin pathway of 5 complement using an acetylated Ficolin-3 ligand, said methods generally comprising the steps of: (a) providing a sample of blood, serum, plasma, another body fluid or an extract thereof; (b) (optionally) preventing in the sample activation of the classical pathway and/or the alternative pathway and/or any non-Ficolin-3 mediated activation of the lectin pathway; (c) acetylating a molecule; (d) contacting said acetylated molecule 10 with said sample, in conditions that permit specific binding of Ficolin-3 to said acetylated molecule, and, (e) detecting and quantifying specific binding of the Ficolin-3 to said acetylated molecule, (f) determining in the sample complement acType: GrantFiled: June 9, 2010Date of Patent: April 21, 2015Assignees: Rigshospitalet, University of CopenhagenInventors: Peter Garred, Christian Honore
-
Patent number: 9005971Abstract: A container system includes a bag having of one or more sheets of flexible polymeric material, the bag having an interior surface at least partially bounding a chamber that is adapted to hold a fluid. A sparger is secured to the interior surface of the bag so that a compartment is formed between the interior surface of the bag and the sparger. At least a portion of the sparger includes a sparging sheet formed from a flexible sheet of a gas permeable material. A tubular port or tube is coupled with the bag so that a passage bounded by the tubular port or tube communicates with the compartment.Type: GrantFiled: December 2, 2013Date of Patent: April 14, 2015Assignee: Life Technologies CorporationInventors: Michael E. Goodwin, Nephi D. Jones, Jeremy K. Larsen
-
Patent number: 8999380Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.Type: GrantFiled: March 9, 2013Date of Patent: April 7, 2015Assignee: Moderna Therapeutics, Inc.Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
-
Patent number: 8999679Abstract: The present invention provides a method for the assembly of a polynucleic acid sequence from a plurality of nucleic acid sequences in which the polynucleic acid sequence is of a formula Nn+1, in which N represents a nucleic acid sequence and where n is 1 or greater than 1 and each N may be the same or a different nucleic acid sequence, in which the method comprises: (i) providing a first nucleic acid sequence N1 which has an oligonucleotide linker sequence L13 at the 3?-end of the nucleic acid sequence; (ii) providing a second nucleic acid sequence N2 which optionally has an oligonucleotide linker sequence L23? at the 3?-end of the nucleic acid sequence and which has an oligonucleotide linker sequence L25? at the 5?-end of the nucleic acid sequence, wherein the 5?-end linker sequence L25? of nucleic acid sequence N2 is complementary to the 3?-end linker sequence L13? of nucleic acid sequence N1; (iii) optionally providing one or more additional nucleic acid sequences N, wherein nucleic acid sequence N2 has anType: GrantFiled: December 18, 2009Date of Patent: April 7, 2015Assignee: Iti Scotland LimitedInventors: Austin Che, Tom Knight, Barry Canton, Jason Kelly, Reshma Shetty
-
Patent number: 8999668Abstract: The present invention relates to a prokaryotic host cell comprising eukaryotic glycosyltransferase activity, where the eukaryotic glycosyltransferase activity is eukaryotic dolichyl-linked UDP-GlcNAc transferase activity and eukaryotic mannosyl-transferase activity. Also disclosed is a method of producing a glycosylated protein by providing a prokaryotic host cell comprising the eukaryotic glycosyltransferase activity and culturing the prokaryotic host cell under conditions effective to produce a glycosylated protein. Another aspect of the present invention pertains to a method for screening bacteria or bacteriophages by expressing one or more glycans on the surface of a bacteria, attaching a label on the one or more glycans on the surface of the bacteria or on the surface of a bacteriophage derived from the bacteria, and analyzing the label in a high-throughput format.Type: GrantFiled: January 5, 2009Date of Patent: April 7, 2015Assignee: Cornell Research Foundation, Inc.Inventors: Matthew DeLisa, Cassandra Guarino, Thomas Mansell, Adam Fisher